Advent International recognized BioDuro as a company uniquely positioned to leverage growth in pharmaceutical R&D outsourcing in China and the US
WuXi AppTec has benefited from being an early mover in China’s pharmaceutical R&D outsourcing space. Founded in 2000 by a team of four working out of a single laboratory, the company is now the runaway...
Ascendent Capital Partners has joined Xuan Ruiguo, the chairman and founder of Hong Kong-listed industrial control systems maker China Automation Group, in a take-private offer that values the company at HK$1.5 billion ($197 million).
Australian investment firm Leap Capital has raised A$50 million ($34 million) for a venture debt fund that will target established, revenue-generating companies locally.
Hansoh Pharmaceutical Group, a Chinese drug developer that counts Hillhouse Capital and Boyu Capital among its investors, has raised HK$7.86 billion ($1 billion) through a Hong Kong IPO.
Fidelity International has announced plans to spin-out its proprietary investment arm Eight Roads within the year pending regulatory and shareholder approvals.